Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs

Oriol Sola Morales is the co-author of an article about reimbursement decisions on new oncology drugs. You can access to the entire article in this link. Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug’s risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. The article explains the authors perspectives on strategies to mitigate sources of uncertainty in the health technology assessment process. These include flexible approaches for evaluating the additional benefit, such as better use of surrogate endpoints and health-related quality of life data, and renewed research efforts to define the optimal target population and generate real-world evidence post-authorisation. KEYWORDS: Oncology, patient access, HTA, reimbursement, surrogate endpoint, Health Related Quality of Life...
Big Data analytical tools project

Big Data analytical tools project

Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures. In order to know which are the needs and the characteristics of the companies that use Big Data analytical tools, HiTT is developing this study through interviews to professionals of different sectors and also, through on-line questionnaires that people that is interested in this topic can answer. We would like to gather as much information as possible to ensure that our analysis reflects the real concerns of the market. HiTT invites the professionals that use big data tools in its analytical procedure, to open this link and answer the questionnaire. Your responses will be kept anonymous. Many thanks in...
New acquisition cost of Repatha

New acquisition cost of Repatha

Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US. This is an excellent message for millions of users who preferred risk to co-pay. It is indeed a significant change, not only for the potential change it is making on access to the drug and the harm to its direct competitor, but also it sends a very powerful message to the community: the drug was overpriced by at least 60%. How do we take it from there? Do we just have to wait 1-2 years to make innovation available so that it reaches the appropriate price? The move is giving payers a strong incentive to keep asking for discounts and only build mistrust on...